97 related articles for article (PubMed ID: 16538101)
1. Individualization of antiviral treatment regimens for chronic hepatitis C.
Paulon E; Naoumov NV
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):321-5. PubMed ID: 16538101
[TBL] [Abstract][Full Text] [Related]
2. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Oct; 84(10):1593-9. PubMed ID: 22930507
[TBL] [Abstract][Full Text] [Related]
3. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
McHutchison JG; Manns M; Patel K; Poynard T; Lindsay KL; Trepo C; Dienstag J; Lee WM; Mak C; Garaud JJ; Albrecht JK;
Gastroenterology; 2002 Oct; 123(4):1061-9. PubMed ID: 12360468
[TBL] [Abstract][Full Text] [Related]
4. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
5. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.
Kondo C; Atsukawa M; Tsubota A; Itokawa N; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Sakamoto C
J Viral Hepat; 2012 Sep; 19(9):615-22. PubMed ID: 22863265
[TBL] [Abstract][Full Text] [Related]
6. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
[TBL] [Abstract][Full Text] [Related]
7. Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.
Mangia A; Mottola L; Piazzolla V
Clin Infect Dis; 2013 May; 56(9):1294-300. PubMed ID: 23271787
[TBL] [Abstract][Full Text] [Related]
8. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
Asahina Y; Izumi N
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
[No Abstract] [Full Text] [Related]
9. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
[TBL] [Abstract][Full Text] [Related]
10. Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
Lee JW; Kim W; Kwon EK; Kim Y; Shin HM; Kim DH; Min CK; Choi JY; Lee WW; Choi MS; Kim BG; Cho NH
PLoS One; 2017; 12(6):e0179094. PubMed ID: 28614389
[TBL] [Abstract][Full Text] [Related]
11. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
12. The evolving treatment of chronic hepatitis C: where we stand a decade out.
Saadeh S; Davis GL
Cleve Clin J Med; 2004 May; 71 Suppl 3():S3-7. PubMed ID: 15468610
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
[TBL] [Abstract][Full Text] [Related]
15. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
16. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of measuring HCV-RNA levels in patients with chronic hepatitis C by IFN treatment, including combination therapy with ribavirin].
Kakumu S
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):507-10. PubMed ID: 15359851
[No Abstract] [Full Text] [Related]
18. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.
Berenguer M; Prieto M; Palau A; Carrasco D; Rayón JM; Calvo F; Berenguer J
Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1207-12. PubMed ID: 15489583
[TBL] [Abstract][Full Text] [Related]
19. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
20. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
Chevaliez S; Hézode C; Soulier A; Costes B; Bouvier-Alias M; Rouanet S; Foucher J; Bronowicki JP; Tran A; Rosa I; Mathurin P; Alric L; Leroy V; Couzigou P; Mallat A; Charaf-Eddine M; Babany G; Pawlotsky JM
Gastroenterology; 2011 Jul; 141(1):119-27. PubMed ID: 21439960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
